Track Medexus Pharmaceuticals Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Medexus Pharmaceuticals Inc. MDP.TO Open Medexus Pharmaceuticals Inc. in new tab

3.28 CAD
P/E
285.00
EPS
-0.03
P/B
1.56
ROE
-0.64
Beta
1.87
Target Price
6.87 CAD
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc.

🧾 Earnings Recap – Q3 2026

Medexus Pharmaceuticals reported solid fiscal Q3 2026 results, reflecting strong early performance from GRAFAPEX amid a challenging revenue environment, generating net revenue of $25.3 million.

  • GRAFAPEX achieved $2 million in product level net revenue during Q3, with expectations to reach $11-$12 million for the entire fiscal year.
  • The company saw a strong rebound in patient demand in January 2026, with a forecast of $3 million to $4 million in net revenue for fiscal Q4.
  • Despite a year-over-year net revenue decline, adjusted EBITDA of $4.5 million shows positive operating income for the third consecutive quarter.
  • Investments in IXINITY manufacturing have led to a 30% reduction in product costs since its acquisition.
  • Rupall faces ongoing generic competition, with anticipated stabilization in future sales declines.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJune 30, 2026
P/E285.00
EPS-0.03
Book Value2.25
Price to Book1.56
Debt/Equity48.55
% Insiders7.332%
Growth
Revenue Growth-0.16%
Earnings Growth-0.92%
Estimates
Forward P/E-175.00
Forward EPS-0.02
Target Mean Price6.87

DCF Valuation

Tweak assumptions to recompute fair value for Medexus Pharmaceuticals Inc. (MDP.TO)
Currency: CAD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Medexus Pharmaceuticals Inc. Logo Medexus Pharmaceuticals Inc. Analysis (MDP.TO)

Canada Healthcare Official Website Stock

Is Medexus Pharmaceuticals Inc. a good investment? Medexus Pharmaceuticals Inc. (MDP.TO) is currently trading at 3.28 CAD. Market analysts have a consensus price target of 6.87 CAD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 285.00. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Medexus Pharmaceuticals Inc. is expected to release its next earnings report on June 30, 2026. The market consensus estimate for Forward EPS is -0.02.

Investor FAQ

Does Medexus Pharmaceuticals Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Medexus Pharmaceuticals Inc.?

Medexus Pharmaceuticals Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be June 30, 2026. The company currently has a trailing EPS of -0.03.

Company Profile

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Exchange Ticker
None MDP.TO
PNK (United States) MEDXF

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Dec. 19, 2018 0.070000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion